Trial Profile
Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs SR 31747 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ODYSSEY
- 22 Dec 2008 Actual initiation date (Oct 2003) added as reported by ClinicalTrials.gov.
- 22 Dec 2008 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
- 22 Dec 2008 Planned number of patients changed from 255 to 232 as reported by ClinicalTrials.gov.